Patricia Villagrasa - Concepedia

Author

Patricia Villagrasa

Also Known As

Adamo, Barbara, Bottosso, M, Conte, P., Gion, Maria, González-Farre, Blanca, Hernando, Cristina, Llombart-Cussac, A, Muñoz, Montserrat, Ogayo, E.R, P Villagrasa

204

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Hospital Clínic de Barcelona Vall d'Hebron Institute of Oncology Consorci Institut D'Investigacions Biomediques August Pi I Sunyer University of North Carolina at Chapel Hill Vall d'Hebron Hospital Universitari

About

Patricia Villagrasa is an author at Hospital Clínic de Barcelona specializing in medicine, breast cancer, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	1.2K
2	Natural Sciences	3	3	216
3	Engineering	1	1	94
4	Health Sciences	1	1	18
5	Nursing	1	1	72

Patricia Villagrasa

Publications

Citations

H-Index

Page 1

	Year	Citations
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer Francesco Schettini, Núria Chic, Fara Brasó‐Maristany, npj Breast Cancer	2021	655
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial Aleix Prat, Cristina Saura, Tomás Pascual, The Lancet Oncology Breast OncologyMedicinePharmacologyGynecologyBreast Cancer	2019	191
Repression of PTEN Phosphatase by Snail1 Transcriptional Factor during Gamma Radiation-Induced Apoptosis Maria Escrivà, Sandra Peiró, Nicolás Herranz, Molecular and Cellular Biology Pten PromoterPten Promoter IncreasesMolecular RegulationApoptosisCell Death	2008	188
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial Sara M. Tolaney, Paolo Tarantino, Noah Graham, The Lancet Oncology Breast OncologyOncologyBreast CancerAdjuvant PaclitaxelCancer Treatment	2023	151
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso‐Sousa, Breast Cancer Research	2020	141
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer Aleix Prat, Valentina Guarneri, Tomás Pascual, EBioMedicine	2022	133
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial Eva Ciruelos, Patricia Villagrasa, Tomás Pascual, Clinical Cancer Research	2020	111
Specific Phosphorylation of p120-Catenin Regulatory Domain Differently Modulates Its Binding to RhoA Julio Castaño, Guiomar Solanas, David Casagolda, Molecular and Cellular Biology Signal TransductionDocking SiteBiochemistryMolecular RegulationTyrosine Residues	2006	108
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade Paolo Nucíforo, Tomás Pascual, Javier Cortés, Annals of Oncology Predictive ModelTumor CellularityCancer ImmunosurveillanceBreast OncologyMedicine	2017	107
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade Fara Brasó‐Maristany, Gaia Griguolo, Tomás Pascual, Nature Communications	2020	105

Page 1